Successful Treatment of Vulvodynia With Botulinum Toxin A

Tieu, Kathy; MacGregor, Jennifer L.

doi:10.1001/archdermatol.2010.443

Cited by 11 publications

(6 citation statements)

References 4 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The literature includes few reports of pelvic pain treatment at pain clinics using minimally invasive interventional procedures (Table ). Lately, however, interest has arisen in specialized pain management techniques, such as multilevel local anesthetic, botulinum toxin A, radiofrequency nerve blockade, and neuromodulation using different modalities of electrical stimulation …”

Section: Nonsurgical Interventional Treatmentmentioning

confidence: 99%

Vulvodynia—An Evidence‐Based Literature Review and Proposed Treatment Algorithm

et al. 2015

View full text Add to dashboard Cite

The optimal therapy for vulvar pain syndrome remains elusive, with low percentages of therapeutic success, using either local or systemic pharmacological approaches. Surgery involving invasive and often irreversible therapeutic procedures has resulted in success for certain subtypes of vulvodynia. We present a multidisciplinary approach whereby pain treatment units may provide an intermediate level of care between standard medical and surgical treatments.

show abstract

Section: Nonsurgical Interventional Treatmentmentioning

confidence: 99%

Vulvodynia—An Evidence‐Based Literature Review and Proposed Treatment Algorithm

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Such therapies are less applicable to generalized vulvodynia, as the injection site(s) is usually limited to the vulvar vestibule and areas immediately surrounding the introitus 37,44-46 . Botulinum toxin A has been most extensively investigated as a possible injectable treatment for vulvodynia 37,44-47 . Botulinum toxin is a neurotoxin derived from bacterial pathogen, Clostridium botulinum 37 .…”

Section: The Elusive Origins Of Vulvodynia and The Unsurprising Treatmentioning

confidence: 99%

“…Botulinum toxin is a neurotoxin derived from bacterial pathogen, Clostridium botulinum 37 . In addition to reduction of superimposed pelvic floor muscle spasm, botulinum toxin may also possess efficacy for vulvodynia due to its ability to inhibit substance P release, a neurotransmitter associated with inflammation and pain 47 . Despite promising results in case studies, the only RCT examining the efficacy of botulinum toxin A failed to show a significant improvement in symptoms versus placebo 46 .…”

Section: The Elusive Origins Of Vulvodynia and The Unsurprising Treatmentioning

confidence: 99%

“…37,[44][45][46] Botulinum toxin A has been most extensively investigated as a possible injectable treatment for vulvodynia. 37,[44][45][46][47] Botulinum toxin is a neurotoxin derived from the bacterial pathogen Clostridium botulinum. 37 In addition to a reduction in superimposed pelvic floor muscle spasm, botulinum toxin may also possess efficacy for vulvodynia because of its ability to inhibit substance P release, a neurotransmitter associated with inflammation and pain.…”

Section: Injectable Agentsmentioning

confidence: 99%

“…37 In addition to a reduction in superimposed pelvic floor muscle spasm, botulinum toxin may also possess efficacy for vulvodynia because of its ability to inhibit substance P release, a neurotransmitter associated with inflammation and pain. 47 Despite promising results in case studies, the only RCT examining the efficacy of botulinum toxin A failed to show a significant improvement in symptoms versus placebo. 46 Injected corticosteroids may also improve pain profiles in women with vulvodynia, which has been attributed to their potential anti-inflammatory effects; 26 however, further investigation is necessary to confirm their effectiveness.…”

Section: Injectable Agentsmentioning

confidence: 99%

See 2 more Smart Citations

A review of the available clinical therapies for vulvodynia management and new data implicating proinflammatory mediators in pain elicitation

Falsetta

Foster

Bonham

et al. 2016

BJOG

View full text Add to dashboard Cite

Localized provoked vulvodynia (LPV) is a common, chronic, and disabling condition; patients experience profound pain and a diminished quality of life. The etiologic origins of vulvodynia are poorly understood, yet recent evidence suggests a link to site-specific inflammatory responses. Fibroblasts isolated from the vestibule of LPV patients are sensitive to pro-inflammatory stimuli and copiously produce pain-associated pro-inflammatory mediators (IL‐6 and PGE2). Although LPV is a multifactorial disorder, understanding vulvar inflammation and targeting the inflammatory response should lead to treatment advances, especially for patients exhibiting signs of inflammation. NFkB (already targeted clinically) or other inflammatory components may be suitable therapeutic targets.

show abstract